The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
Open accessAbstract
BACKGROUND: Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high CV risk. Prior real-world data suggested similar SGLT-2i effects in T2D patients with a broader risk profile, but these studies focused on heart failure and death and were limited to the United States and Europe. OBJECTIVES: The purpose of this study was to examine a broad range of CV outcomes in patients initiated on SGLT-2i versus other glucose-lowering drugs (oGLDs) across 6 countries in the Asia Pacific, the Middle East, and North American regions. METHODS: New users of SGLT-2i and oGLDs were identified via claims, medical records, and national registries in South Korea, Japan, Singapore, Israel, Australia, and Canada. Propensity scores for SGLT-2i initiation were developed in each country, with 1:1 matching. Hazard ratios (HRs) for death, hospitalization for heart failure (HHF), death or HHF, MI, and stroke were assessed by country and pooled using weighted meta-analysis. RESULTS: After propensity-matching, there were 235,064 episodes of treatment initiation in each group; ∼27% had established CV disease. Patient characteristics were well-balanced between groups. Dapagliflozin, empagliflozin, ipragliflozin, canagliflozin, tofogliflozin, and luseogliflozin accounted for 75%, 9%, 8%, 4%, 3%, and 1% of exposure time in the SGLT-2i group, respectively. Use of SGLT-2i versus oGLDs was associated with a lower risk of death (HR: 0.51; 95% confidence interval [CI]: 0.37 to 0.70; p < 0.001), HHF (HR: 0.64; 95% CI: 0.50 to 0.82; p = 0.001), death or HHF (HR: 0.60; 95% CI: 0.47 to 0.76; p < 0.001), MI (HR: 0.81; 95% CI: 0.74 to 0.88; p < 0.001), and stroke (HR: 0.68; 95% CI: 0.55 to 0.84; p < 0.001). Results were directionally consistent across both countries and patient subgroups, including those with and without CV disease. CONCLUSIONS: In this large, international study of patients with T2D from the Asia Pacific, the Middle East, and North America, initiation of SGLT-2i was associated with a lower risk of CV events across a broad range of outcomes and patient characteristics. (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors [CVD-REAL]; NCT02993614).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 5×
“For the outcomes of MI, our results were also directionally consistent with those observed in both EMPA-REG and the CANVAS Program, and for the outcome of stroke, our data were directionally consistent with the CANVAS Program (6,7).”
ResultInfluentialA Note on Robust Variance Estimation for Cluster‐Correlated Data
Williams, R. L. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00645.x · Cited by 2,501
Cohort Profile: The National Health Insurance Service–National Sample Cohort (NHIS-NSC), South Korea
Lee, J., Lee, J. S., Park, S.-H., Shin, S. A., & Kim, K. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyv319 · Cited by 1,469
Self-citationCheol Seong, S., Kim, Y.-Y., Khang, Y.-H., Heon Park, J., Kang, H.-J., Lee, H., Do, C.-H., Song, J.-S., Hyon Bang, J., Ha, S., et al. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw253 · Cited by 1,277 · cited 1×
“The National Health Insurance Service provides a centralized health insurance database that provides longitudinal data for 97% of the Korean population, with linkage to the National Death Registry (10,11).”
BackgroundSelf-citationCardiovascular Disease and Risk Factors in Asia: A Selected Review
Ueshima, H., Sekikawa, A., Miura, K., Turin, T. C., Takashima, N., Kita, Y., Watanabe, M., Kadota, A., Okuda, N., Kadowaki, T., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.790048 · Cited by 919
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813
Self-citationMahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Fabbrini, E., Sun, T., Li, Q., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032038 · Cited by 498
Diabetes in Asia and the Pacific: Implications for the Global Epidemic
Nanditha, A., Ma, R. C. W., Ramachandran, A., Snehalatha, C., Chan, J. C. N., Chia, K. S., Shaw, J. E., & Zimmet, P. Z. (2016) · Diabetes Care · doi:10.2337/dc15-1536 · Cited by 487
Self-citationBirkeland, K. I., Jørgensen, M. E., Carstensen, B., Persson, F., Gulseth, H. L., Thuresson, M., Fenici, P., Nathanson, D., Nyström, T., Eriksson, J. W., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30258-9 · Cited by 362
Self-citationAsia Pacific Cohort Studies Collaboration (2003) · Diabetes Care · doi:10.2337/diacare.26.2.360 · Cited by 300
Harding, J. L., Shaw, J. E., Peeters, A., Cartensen, B., & Magliano, D. J. (2015) · Diabetes Care · doi:10.2337/dc14-1996 · Cited by 286
Self-citationPersson, F., Nyström, T., Jørgensen, M. E., Carstensen, B., Gulseth, H. L., Thuresson, M., Fenici, P., Nathanson, D., Eriksson, J. W., Norhammar, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13077 · Cited by 212
Self-citationDiabetes epidemic sweeping the Arab world
Abuyassin, B., & Laher, I. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i8.165 · Cited by 196
The epidemiology of diabetes in a large Israeli HMO
Chodick, G., Heymann, A. D., Shalev, V., & Kookia, E. (2003) · European Journal of Epidemiology · doi:10.1023/b:ejep.0000006635.36802.c8 · Cited by 175
Self-citationIncidence and Prevalence of Diabetes in Manitoba, 1986–1991
Blanchard, J. F., Ludwig, S., Wajda, A., Dean, H., Anderson, K., Kendall, O., & Depew, N. (1996) · Diabetes Care · doi:10.2337/diacare.19.8.807 · Cited by 174
Shalev, V., Chodick, G., Goren, I., Silber, H., Kokia, E. S., & Heymann, A. D. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.08.002 · Cited by 156
Self-citationLower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc17-1223 · Cited by 133
Eriksson, J. W., Bodegård, J., Nathanson, D., Thuresson, M., Nyström, T., & Norhammar, A. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.055 · Cited by 90
Self-citationNyström, T., Bodegård, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12889 · Cited by 81
Self-citationUrushihara, H., Taketsuna, M., Liu, Y., Oda, E., Nakamura, M., Nishiuma, S., & Maeda, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053224 · Cited by 78
Heymann, A. D., Chodick, G., Halkin, H., Karasik, A., Shalev, V., Shemer, J., & Kokia, E. S. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.07.002 · Cited by 54
Self-citationNyström, T., Bodegård, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.12.004 · Cited by 52
Self-citationTanabe, M., Motonaga, R., Terawaki, Y., Nomiyama, T., & Yanase, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12567 · Cited by 47
Tanabe, M., Nomiyama, T., Motonaga, R., Murase, K., & Yanase, T. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0045-y · Cited by 16
Cited by
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Self-citationJoseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Self-citationSGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Self-citation
Metadata
- Authors
- Kosiborod, M., Lam, C. S. P., Kohsaka, S., Kim, D. J., Karasik, A., Shaw, J., Tangri, N., Goh, S.-Y., Thuresson, M., Chen, H., Surmont, F., Hammar, N., Fenici, P., Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Norhammar, A., Birkeland, K., Jørgensen, M. E., Holl, R. W., Lam, C. S., Gulseth, H. L., Carstensen, B., Bollow, E., Franch-Nadal, J., García Rodríguez, L. A., Karasik, A., Tangri, N., Kohsaka, S., Kim, D. J., Shaw, J., Arnold, S., Goh, S.-Y., Hammar, N., Fenici, P., Bodegård, J., Chen, H., Surmont, F., Nahrebne, K., Blak, B. T., Wittbrodt, E. T., Saathoff, M., Noguchi, Y., Tan, D., Williams, M., Lee, H. W., Greenbloom, M., Kaidanovich-Beilin, O., Yeo, K. K., Bee, Y. M., Khoo, J., Koong, A., Lau, Y. H., Gao, F., Tan, W. B., Kadir, H. A., Ha, K. H., Lee, J., Chodick, G., Melzer Cohen, C., Whitlock, R., Cea Soriano, L., Fernándex Cantero, O., Riehle, E., Ilomaki, J., & Magliano, D.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 71
- Issue
- 23
- Pages
- 2628-2639
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2808467887
- Cited by
- 461
- References
- 27
- FWCI
- 49.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.